Anna Abou-Raya
Anna Abou-Raya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Suzan Abou-Raya
Internal Medicine Department, Alexandria University Faculty of Medicine, Alexandria, Egypt
4 shared publicationsA. Naim
University of Alexandria
3 shared publicationsH. Abuelkheir
University of Alexandria
3 shared publicationsMadihah Helmii
2 shared publicationsS. Abou-Raya
University of Alexandria
2 shared publicationsEman AbdelGhani
Alexandria University, Faculty of Medicine, Internal Medicine, Alexandria, Egypt
1 shared publication
Latest Publications
- 2 April 2026
- Published by Elsevier in Atherosclerosis
- Vol. 416, 120728
Unravelling the bidirectional relationship between breast cancer and cardiovascular disease
- 2 April 2026
- Published by Elsevier in Atherosclerosis
- Vol. 416, 120728
Unravelling the bidirectional relationship between breast cancer and cardiovascular disease
- 17 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): Dangerous duo
- 17 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): Dangerous duo
- Open Access
- 9 December 2022
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 59 (1) , 1-14
Identification of serum micro-RNAs of early knee osteoarthritis in a cohort of Egyptian patients
- 9 December 2022
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 59 (1) , 1-14
Open AccessIdentification of serum micro-RNAs of early knee osteoarthritis in a cohort of Egyptian patients
- 18 January 2018
- Published by Springer Nature
- p. 679-693
Cardiovascular Manifestations of Immune-Mediated Inflammatory Disorders
- 18 January 2018
- Published by Springer Nature
- p. 679-693
Cardiovascular Manifestations of Immune-Mediated Inflammatory Disorders
- Open Access
- 6 December 2012
- Published by Springer Nature
Statins for Digital Ulcers and Raynaud's Phenomenon in systemic sclerosis
- 6 December 2012
- Published by Springer Nature
Open AccessStatins for Digital Ulcers and Raynaud's Phenomenon in systemic sclerosis
- RetractedOpen Access
- 1 December 2012
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (3) , 265-272
The Effect of Vitamin D Supplementation on Inflammatory and Hemostatic Markers and Disease Activity in Patients with Systemic Lupus Erythematosus: A Randomized Placebo-controlled Trial
Objective. Systemic lupus erythematosus (SLE) is a chronic multisystem inflammatory autoimmune disease. Vitamin D has potent immunomodulatory properties that support its use in the treatment of autoimmune conditions, including SLE. We assessed vitamin D status in patients with SLE and determined alterations in inflammatory and hemostatic markers and disease activity before and after vitamin D supplementation. Methods. Patients with SLE (n = 267) were randomized 2:1 to receive either oral cholecalciferol 2000 IU/day or placebo for 12 months. Outcome measures included assessment of alterations in levels of proinflammatory cytokines and hemostatic markers, and improvement in disease activity before and after 12 months of supplementation. Disease activity was measured by the SLE Disease Activity Index. Vitamin D levels were measured by Liaison immunoassay (normal 30–100 ng/ml). Serum levels between 10 and 30 ng/ml were classified as vitamin D insufficiency and levels < 10 ng/ml as vitamin D deficiency. Results. The mean 25(OH)D level at baseline was 19.8 ng/ml in patients compared to 28.7 ng/ml in controls. The overall prevalence of suboptimal and deficient 25(OH)D serum levels among patients with SLE at baseline was 69% and 39%, respectively. Lower 25(OH)D levels correlated significantly with higher SLE disease activity. At 12 months of therapy, there was a significant improvement in levels of inflammatory and hemostatic markers as well as disease activity in the treatment group compared to the placebo group. Conclusion. Vitamin D supplementation in patients with SLE is recommended because increased vitamin D levels seem to ameliorate inflammatory and hemostatic markers and show a tendency toward subsequent clinical improvement. Clinical Trial Registry NCT01425775.
- 1 December 2012
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (3) , 265-272
RetractedOpen AccessThe Effect of Vitamin D Supplementation on Inflammatory and Hemostatic Markers and Disease Activity in Patients with Systemic Lupus Erythematosus: A Randomized Placebo-controlled Trial
Objective. Systemic lupus erythematosus (SLE) is a chronic multisystem inflammatory autoimmune disease. Vitamin D has potent immunomodulatory properties that support its use in the treatment of autoimmune conditions, including SLE. We assessed vitamin D status in patients with SLE and determined alterations in inflammatory and hemostatic markers and disease activity before and after vitamin D supplementation. Methods. Patients with SLE (n = 267) were randomized 2:1 to receive either oral cholecalciferol 2000 IU/day or placebo for 12 months. Outcome measures included assessment of alterations in levels of proinflammatory cytokines and hemostatic markers, and improvement in disease activity before and after 12 months of supplementation. Disease activity was measured by the SLE Disease Activity Index. Vitamin D levels were measured by Liaison immunoassay (normal 30–100 ng/ml). Serum levels between 10 and 30 ng/ml were classified as vitamin D insufficiency and levels < 10 ng/ml as vitamin D deficiency. Results. The mean 25(OH)D level at baseline was 19.8 ng/ml in patients compared to 28.7 ng/ml in controls. The overall prevalence of suboptimal and deficient 25(OH)D serum levels among patients with SLE at baseline was 69% and 39%, respectively. Lower 25(OH)D levels correlated significantly with higher SLE disease activity. At 12 months of therapy, there was a significant improvement in levels of inflammatory and hemostatic markers as well as disease activity in the treatment group compared to the placebo group. Conclusion. Vitamin D supplementation in patients with SLE is recommended because increased vitamin D levels seem to ameliorate inflammatory and hemostatic markers and show a tendency toward subsequent clinical improvement. Clinical Trial Registry NCT01425775.
- 6 July 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (10) , 1121-1126
The inadequacies of musculoskeletal education
Adequate knowledge and clinical competency are essential for sound rheumatology practice. The aim of this study was the assessment of the adequacy of rheumatology education at the primary care level. Two hundred and ninety-seven primary care physicians participated in this cross-sectional survey. Participants were asked to complete a question survey and to take a previously validated rheumatology examination. The participants rated rheumatology education as important but rated the time spent on rheumatology education as poor. More than 80% of the participants reported a low level of confidence in performing a musculoskeletal physical examination. Of the participants, 75% scored 65% or less in the validated rheumatology examination. The findings of the present study indicate that medical education in rheumatology is inadequate at both the basic and clinical levels. The competence level of graduating physicians in musculoskeletal problem solving is inadequate. Furthermore, the time devoted to rheumatology education and training is disproportionately low compared to the frequency of musculoskeletal complaints encountered in general practice.
- 6 July 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (10) , 1121-1126
The inadequacies of musculoskeletal education
Adequate knowledge and clinical competency are essential for sound rheumatology practice. The aim of this study was the assessment of the adequacy of rheumatology education at the primary care level. Two hundred and ninety-seven primary care physicians participated in this cross-sectional survey. Participants were asked to complete a question survey and to take a previously validated rheumatology examination. The participants rated rheumatology education as important but rated the time spent on rheumatology education as poor. More than 80% of the participants reported a low level of confidence in performing a musculoskeletal physical examination. Of the participants, 75% scored 65% or less in the validated rheumatology examination. The findings of the present study indicate that medical education in rheumatology is inadequate at both the basic and clinical levels. The competence level of graduating physicians in musculoskeletal problem solving is inadequate. Furthermore, the time devoted to rheumatology education and training is disproportionately low compared to the frequency of musculoskeletal complaints encountered in general practice.
- 26 February 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 551
Rheumatoid arthritis, periodontal disease and coronary artery disease
- 26 February 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 551
Rheumatoid arthritis, periodontal disease and coronary artery disease
- 27 September 2007
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1110 (1) , 670-680
Statins as Immunomodulators in Systemic Sclerosis
Systemic sclerosis (SSc) has the highest case‐specific mortality among the rheumatic diseases. Vascular dysfunction and structural wall abnormalities are among the earliest and fundamental alterations in SSc. Statins have a number of immunomodulating effects on vascular wall cells, which may modify the progression of vascular injury. The aim of this study was to evaluate the potential efficacy of statin therapy in ameliorating endothelial dysfunction (ED) in SSc by investigating the effect of statins on some markers that reflect endothelial activation in SSc. Forty patients with SSc were randomized into two groups to receive 6 months' treatment with atorvastatin (n= 20; dose, 40 mg/day) or placebo (n= 20) as an adjuvant to existing therapy. Markers of ED including ET‐1, plasma nitrate levels, and thrombomodulin (TM) were evaluated by the enzyme‐linked immunosorbent assay (ELISA) technique. Fibrinogen, high‐sensitivity C‐reactive protein (hsCRP), ESR, lipid peroxide (LP), and malonylaldehyde (MDA) levels were also assessed. Brachial flow‐mediated vasodilatation was assessed by ultrasonography. Patients were studied at base line and after 6 months of statin therapy. After 6 months of therapy, ET‐1, ICAM‐1, sE‐selectin, vWF, fibrinogen, ESR, hsCRP as well as LP and MDA levels declined and NO increased significantly in the statin‐treated SSc group when compared to the placebo‐treated group. Endothelium‐dependent vasodilatation (EDV) improved significantly in the atorvastatin‐treated group. The findings of this study demonstrated statin‐mediated improvements in the endothelial function of SSc patients as well as immunomodulating effects. Statins may thus prove to be an invaluable addition to the therapy of the vasculopathy of SSc.
- 27 September 2007
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1110 (1) , 670-680
Statins as Immunomodulators in Systemic Sclerosis
Systemic sclerosis (SSc) has the highest case‐specific mortality among the rheumatic diseases. Vascular dysfunction and structural wall abnormalities are among the earliest and fundamental alterations in SSc. Statins have a number of immunomodulating effects on vascular wall cells, which may modify the progression of vascular injury. The aim of this study was to evaluate the potential efficacy of statin therapy in ameliorating endothelial dysfunction (ED) in SSc by investigating the effect of statins on some markers that reflect endothelial activation in SSc. Forty patients with SSc were randomized into two groups to receive 6 months' treatment with atorvastatin (n= 20; dose, 40 mg/day) or placebo (n= 20) as an adjuvant to existing therapy. Markers of ED including ET‐1, plasma nitrate levels, and thrombomodulin (TM) were evaluated by the enzyme‐linked immunosorbent assay (ELISA) technique. Fibrinogen, high‐sensitivity C‐reactive protein (hsCRP), ESR, lipid peroxide (LP), and malonylaldehyde (MDA) levels were also assessed. Brachial flow‐mediated vasodilatation was assessed by ultrasonography. Patients were studied at base line and after 6 months of statin therapy. After 6 months of therapy, ET‐1, ICAM‐1, sE‐selectin, vWF, fibrinogen, ESR, hsCRP as well as LP and MDA levels declined and NO increased significantly in the statin‐treated SSc group when compared to the placebo‐treated group. Endothelium‐dependent vasodilatation (EDV) improved significantly in the atorvastatin‐treated group. The findings of this study demonstrated statin‐mediated improvements in the endothelial function of SSc patients as well as immunomodulating effects. Statins may thus prove to be an invaluable addition to the therapy of the vasculopathy of SSc.
- 29 August 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 421-427
Rheumatoid arthritis, periodontal disease and coronary artery disease
Rheumatoid arthritis (RA), periodontal disease (PD), and coronary artery disease (CAD) are common chronic inflammatory diseases. RA is associated with accelerated vascular risk resulting in an increased prevalence of CAD with attendant early mortality and excess morbidity. RA and PD have a common pathobiology. Accordingly, the aim of this study was to evaluate the association between RA, PD, and CAD and the influence of systemic inflammatory factors. A total of 100 active RA patients of which 50 had established CAD and 50 had no CAD were assessed for PD. All subjects underwent a clinical, cardiac, dental, laboratory, and radiological evaluation. Blood samples were obtained, and the level of high sensitivity C-reactive protein (hs-CRP), total white blood counts (WBC), erythrocyte sedimentation rate (ESR), fibrinogen and tumor necrosis factor (TNF) alpha, total cholesterol (TC), and high density lipoprotein (HDL) were assayed. The findings of this study demonstrated an association between RA, PD, and CAD. The RA patients with CAD had significantly more PD than RA patients without CAD. The inflammatory markers, hsCRP, ESR, WBC, fibrinogen, and TNF-α, were raised in all patients but were significantly higher in RA patients with CAD who also had PD. HDL levels were lower in RA patients with CAD when compared to RA patients without CAD. Evidence from this study shows an association between RA, PD, CAD, and systemic levels of the inflammatory mediators. The implication is that inflammation may be the central link between the chronic inflammatory, autoimmune disorders, and atherosclerosis.
- 29 August 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 421-427
Rheumatoid arthritis, periodontal disease and coronary artery disease
Rheumatoid arthritis (RA), periodontal disease (PD), and coronary artery disease (CAD) are common chronic inflammatory diseases. RA is associated with accelerated vascular risk resulting in an increased prevalence of CAD with attendant early mortality and excess morbidity. RA and PD have a common pathobiology. Accordingly, the aim of this study was to evaluate the association between RA, PD, and CAD and the influence of systemic inflammatory factors. A total of 100 active RA patients of which 50 had established CAD and 50 had no CAD were assessed for PD. All subjects underwent a clinical, cardiac, dental, laboratory, and radiological evaluation. Blood samples were obtained, and the level of high sensitivity C-reactive protein (hs-CRP), total white blood counts (WBC), erythrocyte sedimentation rate (ESR), fibrinogen and tumor necrosis factor (TNF) alpha, total cholesterol (TC), and high density lipoprotein (HDL) were assayed. The findings of this study demonstrated an association between RA, PD, and CAD. The RA patients with CAD had significantly more PD than RA patients without CAD. The inflammatory markers, hsCRP, ESR, WBC, fibrinogen, and TNF-α, were raised in all patients but were significantly higher in RA patients with CAD who also had PD. HDL levels were lower in RA patients with CAD when compared to RA patients without CAD. Evidence from this study shows an association between RA, PD, CAD, and systemic levels of the inflammatory mediators. The implication is that inflammation may be the central link between the chronic inflammatory, autoimmune disorders, and atherosclerosis.